CDA | Evidence Driven
CDA | Evidence Driven

Ranibizumab

Details

Files
Generic Name:
Ranibizumab
Project Status:
Complete
Therapeutic Area:
Macular degeneration, age-related
Manufacturer:
Novartis Pharmaceuticals Inc.
Brand Name:
Lucentis
Project Line:
Reimbursement Review
Project Number:
SR0098-000
Performance Metric:
N/A — Predated performance metrics
Submission Type:
Initial
Indications:
Macular degeneration, age-related
Recommendation Type:
List with clinical criteria and/or conditions
Final Recommendation:

Files

Submission Status Report View PDF
Recommendation and Reasons View PDF
Summary of CEDAC Discussion View PDF
Overview of CDR Reports View PDF
Plain Language Recommendation View PDF
Last Updated : July 12, 2007